These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32808083)

  • 1. Intra-procedural anticoagulation and post-procedural hemoglobin fall in atrial fibrillation ablation with minimally interrupted direct oral anticoagulants: comparisons across 4 drugs.
    Sairaku A; Morishima N; Matsumura H; Amioka M; Maeda J; Watanabe Y; Nakano Y
    J Interv Card Electrophysiol; 2021 Sep; 61(3):551-557. PubMed ID: 32808083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
    Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
    Europace; 2014 Oct; 16(10):1443-9. PubMed ID: 25115168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remaining activity of temporary interrupted direct oral anticoagulants and its impact on intra-ablation heparinization in patients with atrial fibrillation: Comparisons across four drugs and two dose regimens.
    Sairaku A; Onohara Y; Hironobe N; Matsumura H; Kihara Y; Nakano Y
    J Cardiovasc Electrophysiol; 2020 Aug; 31(8):1996-2004. PubMed ID: 32459011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2823-2833. PubMed ID: 31701593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of different anticoagulation therapies on heparin dosage applied to atrial fibrillation patients undergoing atrial fibrillation catheter ablation].
    Yang L; Gao LJ; Yin XM; Guo BL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Aug; 47(8):602-607. PubMed ID: 31434430
    [No Abstract]   [Full Text] [Related]  

  • 7. Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: Comparisons across 4 drugs.
    Sairaku A; Nakano Y; Onohara Y; Hironobe N; Matsumura H; Shimizu W; Kihara Y
    Thromb Res; 2019 Nov; 183():119-123. PubMed ID: 31677591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Kinetics of Activated Clotting Time Among Uninterrupted Oral Anticoagulants During Catheter Ablation Procedure.
    Kawaji T; Morimoto T; Aizawa T; Hojo S; Kushiyama A; Yaku H; Nakatsuma K; Kaneda K; Kato M; Yokomatsu T; Miki S; Kimura T
    J Clin Pharmacol; 2022 Jun; 62(6):792-800. PubMed ID: 34921561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and predictors of silent cerebral thromboembolic lesions after catheter ablation for atrial fibrillation in patients treated with direct oral anticoagulants.
    Doi A; Takagi M; Kakihara J; Hayashi Y; Tatsumi H; Fujimoto K; Sugioka K; Yoshiyama M
    Heart Vessels; 2017 Oct; 32(10):1227-1235. PubMed ID: 28466408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
    Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants.
    Nishizaki K; Itoh T; Kimura M; Tsushima Y; Shoji Y; Kinjo T; Ishida Y; Sasaki K; Horiuchi D; Sasaki S; Tomita H; Okumura K
    J Cardiol; 2017 Jul; 70(1):86-91. PubMed ID: 27816321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
    Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
    J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adequate Initial Heparin Dosage for Atrial Fibrillation Ablation in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Komtasubara I; Kusachi S
    Clin Drug Investig; 2016 Oct; 36(10):837-48. PubMed ID: 27389243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial Fibrillation.
    Aoyama D; Miyazaki S; Hasegawa K; Kaseno K; Ishikawa E; Mukai M; Miyahara K; Aiki T; Matsui A; Yamaguchi J; Shiomi Y; Tama N; Ikeda H; Fukuoka Y; Morishita T; Ishida K; Uzui H; Tada H
    Int Heart J; 2019 Nov; 60(6):1315-1320. PubMed ID: 31735780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin.
    Shin DG; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN
    Yonsei Med J; 2016 Mar; 57(2):342-9. PubMed ID: 26847285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation.
    Efremidis M; Vlachos K; Letsas KP; Giannopoulos G; Lioni L; Georgopoulos S; Vadiaka M; Deftereos S; Sideris A
    J Electrocardiol; 2015; 48(5):840-4. PubMed ID: 26152604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated Clotting Time Monitoring during Atrial Fibrillation Catheter Ablation: Does the Anticoagulant Matter?
    Martin AC; Kyheng M; Foissaud V; Duhamel A; Marijon E; Susen S; Godier A
    J Clin Med; 2020 Jan; 9(2):. PubMed ID: 32012701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.